Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > Here’s the problem

<< Previous

Bullboard Posts

Next >>

Comment by Rosmorducon Mar 10, 2020 11:36am

118 Views

Post# 30788555

RE:RE:RE:RE:RE:Here’s the problem

Not really EternalPonzi.

The company has clearly stated that they have enough cash to last them through this year. About 30M$ which is a lot for a company the size of ACST.

The company has also clearly stated that they have no plans for an equity offering or any other means of raising money as it's not necessary.

I suggest you call Investor Relations and speak to them.

The company is very optimisitc with the Trilogy 1 results and will work with their partner to resolve the inconsistency at those 5 sites with the FDA.

Trilogy 2 will be a grand slam.

<< Previous

Bullboard Posts

Next >>

Mid-year review: How has gold been performing?